Comekibart

柯美奇拜单抗

Report date: 2026/05/02 20:00:18

Base Information

Drug NameComekibart
Drug Alias NameMG-K10MG-010MG-K-10BC-005
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin-4 receptor subunit alpha
Therapy Area/IndicationsPrurigo NodularisChronic UrticariaDermatitis, Atopic +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesShanghai Mabgeek Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Maiji Pharmaceutical Co LtdChina Medical System Holdings LtdShanghai Mabgeek Biotechnology Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsPrurigo NodularisChronic UrticariaDermatitis, Atopic +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A